Inquiry Basket
Loading ......
Filter By Product Search for
Acetylcholine
Acetylcholine Full Name
Acetylcholine
Acetylcholine Introduction
Acetylcholine (ACh) is one of the most extensively studied neurotransmitters, yet researchers and drug developers still face persistent challenges in linking its diverse receptor systems to specific therapeutic outcomes. Synthesized from choline and acetyl-CoA by choline acetyltransferase, acetylcholine acts through two major receptor classes: nicotinic acetylcholine receptors (nAChRs), which are ligand-gated ion channels, and muscarinic acetylcholine receptors (mAChRs), which are G protein–coupled receptors. Among these, the α7 nicotinic receptor encoded by the CHRNA7 gene has gained particular attention due to its high calcium permeability and rapid desensitization kinetics, making it uniquely suited for modulating synaptic plasticity and neuroinflammatory signaling. The complexity of acetylcholine signaling—spanning central and peripheral nervous systems, neuromuscular junctions, and non-neuronal tissues—creates a major bottleneck for precise target validation, especially when receptor subtype distribution and downstream signaling pathways vary significantly across tissues.
Functionally, acetylcholine plays a central role in cognition, memory formation, attention, and autonomic regulation, but its relevance extends far beyond neurotransmission. In the brain, nAChRs such as α4β2 and α7 subtypes regulate neurotransmitter release, synaptic plasticity, and neuronal survival, directly influencing learning and executive function. At the same time, acetylcholine is a key mediator of the "cholinergic anti-inflammatory pathway," where activation of α7 receptors on immune cells suppresses pro-inflammatory cytokine release, providing a mechanistic bridge between the nervous and immune systems. This dual role introduces both opportunity and complexity in drug development: targeting acetylcholine receptors can simultaneously modulate neural circuits and systemic inflammation, but off-target effects and receptor desensitization remain significant hurdles. As a result, current strategies increasingly focus on subtype-selective agonists, partial agonists, and positive allosteric modulators to achieve more controlled and sustained therapeutic effects.
Dysregulation of acetylcholine signaling is strongly implicated in a wide spectrum of diseases, making it a high-value but technically challenging target space. In neurodegenerative disorders such as Alzheimer's disease, reduced cholinergic transmission and loss of basal forebrain cholinergic neurons correlate with cognitive decline, which is why acetylcholinesterase inhibitors remain a mainstay of symptomatic treatment. Meanwhile, alterations in nAChR subunit genes—including CHRNA7, CHRNA4, and CHRNB2—have been linked to cognitive impairment, schizophrenia, attention deficit hyperactivity disorder, and epilepsy, often through disrupted receptor expression or function. Beyond the central nervous system, impaired cholinergic signaling contributes to inflammatory diseases, cardiovascular dysfunction, and even cancer progression via tumor microenvironment modulation. Emerging evidence further suggests that upregulation of α7 nAChR may confer neuroprotective and anti-aging effects by enhancing anti-inflammatory capacity and reducing oxidative stress, positioning acetylcholine-related targets as promising candidates for next-generation therapeutics aimed at both neurological and systemic diseases.
Alternate Names for Acetylcholine
[2 (acetyloxy) ethyl] trimethylammonium; ACh; (2-acetoxyethyl) trimethylammonium; 2-acetyloxyethyl-trimethyl-ammonium; Acetylcholine; O-Acetylcholine; ACETYLECHOLINE
Loading ......
